Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications

Journal of Sexual Medicine

Volumn 7, Issue 1 PART 1, 2010, Pages 244-255

  Eardley, Ian ^a   Lee, Jay C ^b   Shabsigh, Ridwan ^c   Dean, John ^d   Maggi, Mario ^e   Neuser, Dieter ^f   Norenberg, Christiane ^f  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CALGARY   (Canada)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d St Peter's Andrology Centre   (United Kingdom)

^e UNIVERSITY OF FLORENCE   (Italy)

^f BAYER PHARMA AG   (Germany)

Author keywords

Concomitant medications; Erectile dysfunction; Phosphodiesterase Type 5 inhibitor; Retrospective analysis; Underlying conditions; Vardenafil

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; THIAZIDE DIURETIC AGENT; VARDENAFIL;

ADULT; ARTICLE; DIABETES MELLITUS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; FLUSHING; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NOSE CONGESTION; PENIS ERECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION;

EID: 74049102684     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01547.x     Document Type: Article

References (47)

1. NIH consensus development panel on impotence. JAMA 1993, 270:83-90. NIH Consensus Conference. Impotence
2. Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction. Int J Impot Res 2003, 15:63-71.
3. Parazzini F, Menchini Fabris F, Bortolotti A, Calabro A, Chatenoud L, Colli E, Landoni M, Lavezzari M, Turchi P, Sessa A, Mirone V. Frequency and determinants of erectile dysfunction in Italy. Eur Urol 2000, 37:43-9.
4. Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: A pathological link supporting cardiovascular diseases. Int J Androl 2009, Feb 10 [Epub ahead of print] doi: 10.1111/j.1365-2605.2008.00951.x
5. Gaskell P. The importance of penile blood pressure in cases of impotence. Can Med Assoc J 1971, 105:1047-51.
6. Inman BA, Sauver JL, Jacobson DJ, McGree ME, Nehra A, Lieber MM, Roger VL, Jacobsen SJ. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009, 84:108-13.
7. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: New guidelines for sexual medicine. J Sex Med 2006, 3:28-36. discussion 36
8. Eardley I, Fisher W, Rosen RC, Niederberger C, Nadel A, Sand M. The multinational Men's Attitudes to Life Events and Sexuality Study: The influence of diabetes on self-reported erectile function, attitudes and treatment-seeking patterns in men with erectile dysfunction. Int J Clin Pract 2007, 61:1446-53.
9. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004, 20:607-17.
10. De Berardis G, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, Pellegrini F, Sacco M, Tognoni G, Valentini M, Nicolucci A. Erectile dysfunction and quality of life in type 2 diabetic patients: A serious problem too often overlooked. Diabetes Care 2002, 25:284-91.
11. Sasaki H, Yamasaki H, Ogawa K, Nanjo K, Kawamori R, Iwamoto Y, Katayama S, Shirai M. Prevalence and risk factors for erectile dysfunction in Japanese diabetics. Diabetes Res Clin Pract 2005, 70:81-9.
12. Burchardt M, Burchardt T, Baer L, Kiss AJ, Pawar RV, Shabsigh A, de la Taille A, Hayek OR, Shabsigh R. Hypertension is associated with severe erectile dysfunction. J Urol 2000, 164:1188-91.
13. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994, 151:54-61.
14. Penson DF, Latini DM, Lubeck DP, Wallace KL, Henning JM, Lue TF. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care 2003, 26:1093-9.
15. Walczak MK, Lokhandwala N, Hodge MB, Guay AT. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 2002, 5:19-24.
16. Nikoobakht M, Nasseh H, Pourkasmaee M. The relationship between lipid profile and erectile dysfunction. Int J Impot Res 2005, 17:523-6.
17. Ponholzer A, Temml C, Rauchenwald M, Madersbacher S. Vascular risk factors and erectile dysfunction in a cohort of healthy men. Int J Impot Res 2006, 18:489-93.
18. Montague DK, Jarow JP, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Milbank AJ, Nehra A, Sharlip ID. Chapter 1: The management of erectile dysfunction: An AUA update. J Urol 2005, 174:230-9.
19. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, Vardi Y. EAU guidelines on erectile dysfunction: An update. Eur Urol 2006, 49:806-15.
20. Sadovsky R, Brock GB, Gutkin SW, Sorsaburu S. Toward a new " EPOCH": Optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. Int J Clin Pract 2009, 63:1214-30.
21. Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bandel TJ, Porst H. The efficacy and safety of flexible-dose vardenafil (Levitra®) in a broad population of European men. Eur Urol 2004, 45:634-41. discussion 641
22. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H. Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002, 23:763-71.
23. Stief C, Porst H, Saenz, De Tejada I, Ulbrich E, Beneke M. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 2004, 58:230-9.
24. Jannini EA, Isidori AM, Gravina GL, Aversa A, Balercia G, Bocchio M, Boscaro M, Carani C, Corona G, Fabbri A, Foresta C, Forti G, Francavilla S, Granata AR, Maggi M, Mansani R, Palego P, Spera G, Vetri M, Lenzi A. The ENDOTRIAL study: A spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J Sex Med 2009, 6:2547-60.
25. Miner M, Gilderman L, Bailen J, Cook D, Dawson K, Stanislaus M, Beresford E, Barnes A. Vardenafil in men with stable statin therapy and dyslipidemia. J Sex Med 2008, 5:1455-67.
26. Welcome to MedDRA and the MSSO. March 1, 2009. http://www.meddramsso.com/MSSOWeb/index.htm, Available at: (accessed April 22, 2009
27. Complete ATC/DDD Index 2009. April 15, 2009. http://www.whocc.no/atcddd/, Available at: (accessed April 22, 2009
28. The IDF consensus worldwide definition of the metabolic syndrome 2006, 24. IDF Writing Group, Brussels, IDF Communications
29. Giuliano F, Rubio-Aurioles E, Kennelly M, Montorsi F, Kim ED, Finkbeiner AE, Pommerville PJ, Colopy MW, Wilkins HJ, Wachs BH. Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury. Neurology 2006, 66:210-6.
30. Rosen R, Shabsigh R, Berber M, Assalian P, Menza M, Rodriguez-Vela L, Porto R, Bangerter K, Seger M, Montorsi F. Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: The depression-related improvement with vardenafil for erectile response study. Am J Psychiatry 2006, 163:79-87.
31. Carson CC, Hatzichristou DG, Carrier S, Lording D, Lyngdorf P, Aliotta P, Auerbach S, Murdock M, Wilkins HJ, McBride TA, Colopy MW. Erectile response with vardenafil in sildenafil nonresponders: A multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int 2004, 94:1301-9.
32. Ralph D, Eardley I, Kell P, Dean J, Hackett G, Collins O, Edwards D. Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners. BJU Int 2007, 100:130-6.
33. Martin-Morales A, Meijide F, Garcia N, Artes M, Munoz A. Efficacy of vardenafil and influence on self-esteem and self-confidence in patients with severe erectile dysfunction. J Sex Med 2007, 4:440-7.
34. Edwards D, Hackett G, Collins O, Curram J. Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): A randomized, double-blind, placebo-controlled trial in PDE5 inhibitor-naive men with ED and their partners. J Sex Med 2006, 3:1028-36.
35. Fisher WA, Rosen RC, Mollen M, Brock G, Karlin G, Pommerville P, Goldstein I, Bangerter K, Bandel TJ, Derogatis LR, Sand M. Improving the sexual quality of life of couples affected by erectile dysfunction: A double-blind, randomized, placebo-controlled trial of vardenafil. J Sex Med 2005, 2:699-708.
36. van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005, 2:856-64.
37. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003, 26:777-83.
38. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med 2009, 6:1232-47.
39. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989, 320:1025-30.
40. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: Analysis of data from tadalafil clinical trials. Diabetologia 2004, 47:1914-23.
41. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999, 281:421-6.
42. Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006, 3:883-91.
43. Vardi M, Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev 2007, CD002187.
44. Weiss RJ. Effects of antihypertensive agents on sexual function. Am Fam Physician 1991, 44:2075-82.
45. Corona G, Razzoli E, Forti G, Maggi M. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 2008, 31:799-808.
46. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone survey. JAMA 2002, 287:337-44.
47. Wong J, Patel RA, Kowey PR. The clinical use of angiotensin-converting enzyme inhibitors. Prog Cardiovasc Dis 2004, 47:116-30.